Skip to main content
LLYX logo

Daily Target 2X Long LLY ETF (LLYX) Fund Overview

Educational signal · not a buy or sell recommendation · How to read this

$23.85 -$0.28 (-1.16%)
Vol: 179.3K|

Beta 0.68: the stock has moved about 32% less than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Daily Target 2X Long LLY ETF (LLYX) trades at $23.85. Daily Target 2X Long LLY ETF (LLYX) is an actively managed exchange-traded fund designed to deliver twice the daily percentage change of Eli Lilly and Company's common stock. Sector: Financials.

Price as of · Last analyzed: Jun 15, 2026
Daily Target 2X Long LLY ETF (LLYX) is an actively managed exchange-traded fund designed to deliver twice the daily percentage change of Eli Lilly and Company's common stock. It utilizes derivatives like swaps and options, resetting daily, making it a short-term trading instrument for amplified exposure to LLY's movements.

Analyst Coverage for LLYX: LLYX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

▶ Watch the LLYX film Every key number, told as a short cinematic story — just press play. ~2 min

Daily Target 2X Long LLY ETF (LLYX) Financial Services Profile

HeadquartersSan Diego, US
IPO Year2024

Daily Target 2X Long LLY ETF is an actively managed, non-diversified exchange-traded fund aiming to deliver twice the daily price movement of Eli Lilly and Company's common stock. Utilizing derivatives like swaps and options, it serves as a short-term trading instrument for investors seeking amplified daily exposure within the financial services sector.

Data Provenance | Financial Data Quantitative Analysis Analysis: Jun 15, 2026

What Is the Investment Thesis for LLYX?

AI-written as of Jun 15, 2026 — figures and tone reflect the data available then, not today's score.

The investment thesis for LLYX centers on its capacity to provide magnified daily exposure to Eli Lilly and Company (LLY) stock, targeting 200% of its daily price movement. This structure serves as a value driver for short-term traders seeking to capitalize on anticipated strong daily performance in LLY, offering amplified gains. The primary growth catalyst for LLYX is sustained positive daily performance in Eli Lilly's stock, particularly during periods of significant upward momentum driven by drug approvals, strong clinical trial results, or positive earnings surprises. Its non-diversified nature and reliance on derivatives mean its performance is directly tied to LLY's daily fluctuations. However, significant risk factors include the potential for amplified losses in declining or volatile markets, the erosive effects of daily compounding over extended holding periods, and the inherent complexities of derivative-based strategies. The fund's daily reset mechanism makes it unsuitable for long-term buy-and-hold strategies, necessitating constant monitoring of LLY's performance and market conditions. Its market capitalization of $0.12B indicates a relatively smaller fund size within the leveraged ETF landscape.

Based on FMP financials and quantitative analysis

LLYX Key Highlights

AI-written as of Jun 15, 2026 — figures and tone reflect the data available then, not today's score.

Market Capitalization: $0.12 billion, indicating a smaller, specialized fund within the leveraged ETF landscape.

  • Beta: 0.68, suggesting lower volatility relative to the broader market for the ETF itself, not its underlying leveraged exposure.
  • Dividend Yield: None, as LLYX is a leveraged ETF focused on amplifying daily price movements rather than generating income.
  • Target Leverage: Aims for 200% of Eli Lilly and Company's (LLY) daily price movement, achieved through derivative instruments.
  • Operational Basis: Non-diversified, concentrating all investment exposure on a single underlying security, Eli Lilly and Company.

What Are LLYX's Key Strengths?

Amplified daily returns: Offers 200% of LLY's daily gains, appealing to short-term bullish traders seeking magnified exposure.

  • Accessibility: Trades like a stock on an exchange, providing easier access to leveraged exposure than direct derivatives for some investors.
  • Focus on a prominent stock: Provides leveraged exposure to a well-known, actively traded and fundamentally strong company like Eli Lilly.

What Are LLYX's Weaknesses?

Amplified losses: Magnifies daily losses by 200%, leading to rapid capital erosion in adverse market conditions.

  • Compounding risk: Daily reset mechanism can lead to significant value decay over holding periods longer than one day, especially in volatile or sideways markets.
  • Non-diversified: Concentrated risk on a single underlying security (LLY), making it vulnerable to company-specific negative events.
  • Complex structure: Requires a deep understanding of leveraged ETFs and derivative mechanics for appropriate use.

What Are the Key Risks for LLYX?

Compounding risk: The daily reset mechanism of the ETF can lead to significant erosion of value over holding periods longer than one day, particularly in volatile or sideways markets.

  • Amplified losses: Any daily decline in Eli Lilly's stock price is magnified by 200%, leading to rapid and substantial capital loss for investors.
  • Regulatory scrutiny: Leveraged and single-stock ETFs may face increased regulatory oversight or restrictions, impacting their operation or availability.
  • Concentration risk: The fund's non-diversified nature means its performance is entirely dependent on a single stock, Eli Lilly, making it vulnerable to company-specific negative news or events.
  • Market volatility: Extreme market volatility or 'gap' openings in LLY's stock price can make it challenging for the ETF to precisely track its 2x daily target, leading to tracking error.

What Threats Does LLYX Face?

  • Extended periods of Eli Lilly stock decline or high volatility, which can severely erode the fund's value due to compounding and amplified losses.
  • Potential regulatory changes impacting leveraged products or derivative use, which could affect the fund's operation or availability.
  • Intense competition from other leveraged products, inverse ETFs, or direct derivative trading strategies on LLY.
  • Lack of understanding by retail investors leading to inappropriate use and negative sentiment towards leveraged ETFs.

What Are LLYX's Competitive Advantages?

  • Specialized product offering: Provides unique 2x daily leveraged exposure to a specific, high-profile stock (Eli Lilly), catering to a niche demand within the financial markets.
  • Expertise in derivative management: The active management of complex swap and option contracts to consistently achieve the 200% daily target requires specialized financial engineering and trading expertise.
  • ETF structure: Offers the liquidity and accessibility of an ETF wrapper, which can be more appealing and easier to trade for some investors compared to direct derivative contracts, providing a regulated investment vehicle.

What Does LLYX Do?

Daily Target 2X Long LLY ETF (LLYX) is an actively managed Exchange Traded Fund (ETF) that operates within the specialized segment of leveraged financial products. Its core objective is to deliver amplified returns, specifically targeting twice (200%) the daily percentage price movement of its underlying security, the common stock of Eli Lilly and Company (LLY). This ambitious objective is pursued through the strategic deployment of sophisticated derivative instruments, primarily including swap agreements and/or listed options contracts. These derivatives are carefully managed to synthetically replicate and magnify the daily performance of Eli Lilly's shares. A defining characteristic of LLYX is its daily reset mechanism, meaning its leverage is rebalanced at the end of each trading day. This design makes it fundamentally a short-term trading instrument, rather than a vehicle for long-term investment, as the effects of compounding over extended periods can significantly impact returns. The fund operates on a non-diversified basis, concentrating its entire exposure on a single underlying asset, Eli Lilly. This singular focus means its performance is intricately linked to the daily fluctuations and specific news events pertaining to the pharmaceutical giant. LLYX caters to a niche market of sophisticated investors and traders who possess a strong short-term directional conviction on Eli Lilly's stock and are comfortable with the elevated risks associated with leveraged products. Its market position is defined by providing a convenient, exchange-traded avenue for magnified daily exposure to a prominent individual equity within the broader financial services and asset management industry.

What Products and Services Does LLYX Offer?

  • Provides 200% (2x) the daily percentage change of Eli Lilly and Company (LLY) common stock.
  • Achieves its leverage target through the use of derivative instruments, such as swap agreements and listed options contracts.
  • Resets its leverage daily, meaning its performance is calculated on a day-to-day basis.
  • Operates as an actively managed Exchange Traded Fund (ETF) within the financial services sector.
  • Is non-diversified, focusing solely on the performance of a single underlying security (LLY).
  • Aims to amplify gains when Eli Lilly's stock performs well on a given day.
  • Is designed as a short-term trading instrument, not a long-term investment vehicle.

How Does LLYX Make Money?

  • Generates revenue through management fees charged to investors for actively managing the fund and its derivative positions.
  • Employs a strategy of using derivatives (swaps, options) to synthetically replicate and amplify the daily price movements of Eli Lilly's stock.
  • Benefits from increased assets under management (AUM) as more investors utilize the fund for short-term leveraged exposure to LLY.

What Industry Does LLYX Operate In?

LLYX operates within the specialized and rapidly evolving leveraged exchange-traded fund (ETF) segment of the financial services industry, specifically asset management. This segment caters to sophisticated investors and traders seeking amplified exposure to specific market movements or individual securities. A key market trend is the increasing demand for tactical trading instruments that allow for precise, short-term bets on market direction. Leveraged ETFs like LLYX compete with other derivative products, such as futures, options, and contracts for difference (CFDs), as well as other leveraged ETFs tracking different indices or sectors. The competitive landscape is characterized by product innovation and the ability to accurately track amplified daily returns. LLYX differentiates itself by offering 2x daily leverage specifically on Eli Lilly's common stock, appealing to investors with a strong conviction on LLY's short-term trajectory. The broader asset management industry is seeing growth in passive and active ETFs, but leveraged funds represent a niche, higher-risk category.

Who Are LLYX's Key Customers?

  • Sophisticated individual traders seeking amplified daily returns on Eli Lilly stock.
  • Institutional investors and hedge funds employing tactical, short-term trading strategies.
  • Investors with a strong short-term directional conviction on Eli Lilly's stock performance.
Model self-rating on this text: 68% (not a measure of the evidence) Updated: Jun 15, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● Price is current
  • ● No filing on record
  • ● No analyst coverage
  • ● This is an etf, not an operating company

MoonshotScore History

Recorded daily since 2026-08-23 · 41 snapshots

2026-08-23 46
2026-08-31 46
2026-09-08 46
2026-09-16 46
2026-09-24 46
2026-10-04 46

What changed?

The score has stayed at 46.

Over the same 30 days the stock moved -4.3%.

LLYX Financials

Bull Case vs Bear Case

Bull Case

  • Amplified daily returns: Offers 200% of LLY's daily gains, appealing to short-term bullish traders seeking magnified exposure.
  • Accessibility: Trades like a stock on an exchange, providing easier access to leveraged exposure than direct derivatives for some investors.
  • Focus on a prominent stock: Provides leveraged exposure to a well-known, actively traded and fundamentally strong company like Eli Lilly.
  • Upcoming: Positive clinical trial results or regulatory approvals for Eli Lilly's pipeline drugs, potentially driving significant upward daily price movements in LLY.

Bear Case

  • Amplified losses: Magnifies daily losses by 200%, leading to rapid capital erosion in adverse market conditions.
  • Compounding risk: Daily reset mechanism can lead to significant value decay over holding periods longer than one day, especially in volatile or sideways markets.
  • Non-diversified: Concentrated risk on a single underlying security (LLY), making it vulnerable to company-specific negative events.
  • Complex structure: Requires a deep understanding of leveraged ETFs and derivative mechanics for appropriate use.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026

LLYX Latest News

No recent news available for LLYX.

LLYX Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for LLYX.

Price Targets

Wall Street price target analysis for LLYX.

LLYX MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for LLYX; grades run from A+ (80-100) to F (below 30).

Daily Target 2X Long LLY ETF Financials Stock: Key Questions Answered

Why is LLYX considered a short-term trading instrument rather than a long-term investment?

LLYX is explicitly designed as a short-term trading instrument due to its daily reset mechanism and the effects of compounding. The fund aims to deliver 200% of the *daily* percentage change of Eli Lilly's stock. This means its performance is calculated anew each day.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

MoonshotScore is not published for this security.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information strictly limited to provided source data. ETF-specific characteristics have been emphasized.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis